Next week, FDA committee of outside experts will meet to review risk-management plans
In the latest step to combat the epidemic of opioid abuse, U.S. officials urge generic drug makers to make changes to opioids.
Mainly supportive of guidelines, but concerns include a lack of evidence underlying some new recommendations.
How can accidental exposure/leaks when handling chemotherapy drugs that incompatible with the closed system device (CSD) be prevented?
ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.
Is there a new consensus about wearing personal protective equipment (PPE) when handling monoclonal antibodies (MABs) for infusion?
The U.S. Drug Enforcement Administration (DEA) to enact tough new controls on painkillers containing hydrocodone, which has been tied to a surge in addictions across the United States.
The FDA issued an alert last Friday that some patients have reported feeling intoxicated after receiving their infusions of the chemotherapeutic drug, docetaxel.
A potent, liquid form of nicotine poses a serious and potentially deadly threat, but is sold legally in stores across the United States and online.
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Although chemotherapy drugs can be lifesaving for patients with cancer, they can be toxic to nurses and other health care personnel who handle them. Nurses should protect themselves through the use of proper handling techniques. A regular review of safe chemotherapy...
Does consumption of regular orange juice cause drug interactions, or should all citrus fruits be avoided?
Project Improves Knowledge, Skills of Non-Chemotherapy Nurse Providers in Caring for Patients Requiring ChemotherapyApril 27, 2013
A program that educates non-chemotherapy provider nurses about how to administer and safely handle chemotherapy drugs improved their knowledge and skills, found research presented at the 38th ONS Annual Congress,
Implementing closed-system transfer devices minimized variability in infusion setup of hazardous drugs, which also limited occupational exposure while standardizing administration, found research presented at the ONS 38th Annual Congress.
Which medicines can be split or crushed for administration?
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics.
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon.
What vaccines are appropriate or not appropriate for cancer patients?
To assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
Which antidepressants are important to be aware of with patients on tamoxifen (Nolvadex)?
The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.
What is the significance of food-drug interactions especially with oral agents such as nilotinib (Tasigna), sunitinib (Sutent), sorafenib (Nexavar), and erlotinib (Tarceva), to name a few?
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.
Persons with cancer who use herbs or dietary supplements are at risk for harmful drug interactions, a new study has reiterated.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|